Research Progress on the Role of Enzymes Involved in Histone Methylation in Hepatocellular Carcinoma
Abnormal histone modification plays an important role in the occurrence and development of hepatocellular carcinoma (HCC). As an important histone modification pattern, histone methylation is closely related to the occurrence and development of HCC. In recent years, a large number of studies have shown that abnormal histone methylation is involved in the proliferation, invasion, and metastasis of HCC and is related to the prognosis of HCC patients. Enzymes associated with histone methylation play an important role in the histone methylation process. Exploration of the relationship between histone methylation and HCC, and in-depth studies on the pathogenesis of the disease would contribute to the finding of tumor markers and the development of targeted drugs, which is of great significance for the diagnosis, treatment, and prognosis of patients with HCC. This review summarizes the research progress regarding the enzymes involved in histone methylation in HCC.
Ricketts MD, Han J, Szurgot MR, et al., 2019, Molecular Basis for Chromatin Assembly and Modification by Multiprotein Complexes. Protein Sci, 28:329–43.
Urulangodi M, Mohanty A, 2020, DNA Damage Response and Repair Pathway Modulation by Non-histone Protein Methylation: Implications in Neurodegeneration. J Cell Commun Signal, 14:31–45. DOI: 10.1007/s12079-019-00538-2.
Shechter D, 2019, Introduction to the Multi-author Review on Methylation in Cellular Physiology. Cell Mol Life Sci, 76:2871–2. DOI: 10.1007/s00018-019-03141-1.
Greer EL, Shi Y, 2012, Histone Methylation: A Dynamic Mark in Health, Disease and Inheritance. Nat Rev Genet, 13:343–57. DOI: 10.1038/nrg3173.
Li AS, Li F, Eram MS, et al., 2020, Chemical Probes for Protein Arginine Methyltransferases. Methods (San Diego, Calif), 175:30–43. DOI: 10.1016/j.ymeth.2019.11.017.
Blanc RS, Richard S, 2017, Arginine Methylation: The Coming of Age. Mol. Cell, 65:8–24.
Cheng D, Côté J, Shaaban S, et al., 2007, The Arginine Methyltransferase CARM1 Regulates the Coupling of Transcription and mRNA Processing. Mol. Cell, 25:71–83. DOI: 10.1016/j.molcel.2006.11.019.
Kaniskan H, Jin J, 2015, Chemical Probes of Histone Lysine Methyltransferases. ACS Chem Biol, 10:40–50. DOI: 10.1021/cb500785t.
Zhang L, Ma H, 2012, Complex Evolutionary History and Diverse Domain Organization of SET Proteins Suggest Divergent Regulatory Interactions. New Phytol, 195:248–63. DOI: 10.1111/j.1469-8137.2012.04143.x.
Casciello F, Al-Ejeh F, Kelly G, et al., 2017, G9a Drives Hypoxia-mediated Gene Repression for Breast Cancer Cell Survival and Tumorigenesis. Proc Natl Acad Sci U S A, 114:7077–82. DOI: 10.1073/pnas.1618706114.
Wu H, Chen X, Xiong J, et al., 2011, Histone Methyltransferase G9a Contributes to H3K27 Methylation In Vivo. Cell Res, 21:365–7.
Wysocka J, Allis CD, Coonrod S, 2006, Histone Arginine Methylation and its Dynamic Regulation. Front. Biosci, 11:344–55. DOI: 10.2741/1802.
Jiang H, Zhou Z, Jin S, et al., 2018, PRMT9 Promotes Hepatocellular Carcinoma Invasion and Metastasis via Activating PI3K/Akt/GSK-3b/Snail Signaling. Cancer Sci, 109:1414–27. DOI: 10.1111/cas.13598.
Fulton MD, Brown T, Zheng YG, 2018, Mechanisms and Inhibitors of Histone Arginine Methylation. Chem Record (New York, NY), 18:1792–807.
Stopa N, Krebs JE, Shechter D, 2015, The PRMT5 Arginine Methyltransferase: Many Roles in Development, Cancer and Beyond. Cell Mol Life Sci, 72:2041–59. DOI: 10.1007/s00018-015-1847-9.
Zhang B, Dong S, Li Z, et al., 2015, Targeting Protein Arginine Methyltransferase 5 Inhibits Human Hepatocellular Carcinoma Growth Via the Downregulation of Beta-catenin. J Transl Med, 13:349. DOI: 10.1186/s12967-015-0721-8.
Zhang W, Chen J, Wu M, et al., 2017, PRMT5 Restricts Hepatitis B Virus Replication through Epigenetic Repression of Covalently Closed Circular DNA Transcription and Interference with Pregenomic RNA Encapsidation. Hepatology (Baltimore, MD), 66:398–415. DOI: 10.1002/hep.29133.
Wei H, Liu Y, Min J, et al., 2019, Protein Arginine Methyltransferase 1 Promotes Epithelial-mesenchymal Transition via TGF-b1/Smad Pathway in Hepatic Carcinoma Cells. Neoplasma, 66:918–29. DOI: 10.4149/neo_2018_181226n999.
Chen S, Pu J, Bai J, et al., 2018, EZH2 Promotes Hepatocellular Carcinoma Progression through Modulating miR-22/galectin-9 Axis. J Exp Clin Cancer Res, 37:3. DOI: 10.1186/s13046-017-0670-6.
Xiao G, Jin LL, Liu CQ, et al., 2019, EZH2 Negatively Regulates PD-L1 Expression in Hepatocellular Carcinoma. J Immunother Cancer, 7:300.
Cheng XS, Sun SB, Zhong F, et al., 2016, Knockdown of Histone Methyltransferase hSETD1A Inhibits Progression, Migration, and Invasion in Human Hepatocellular Carcinoma. Oncol Res, 24:239–45. DOI: 10.3727/096504016x14648701448011.
Wu J, Chai H, Li F, et al., 2020, SETD1A Augments Sorafenib Primary Resistance Via Activating YAP in Hepatocellular Carcinoma. Life Sci, 260:118406. DOI: 10.1016/j.lfs.2020.118406.
Cheng X, Hao Y, Shu W, et al., 2017, Cell Cycle-dependent Degradation of the Methyltransferase SETD3 Attenuates Cell Proliferation and Liver Tumorigenesis. J Biol Chem, 292:9022–33. DOI: 10.1074/jbc.m117.778001.
Xu L, Wang P, Feng X, et al., 2019, SETD3 is Regulated by a Couple of microRNAs and Plays Opposing Roles in Proliferation and Metastasis of Hepatocellular Carcinoma. Clin Sci (London, England: 1979), 133:2085–105. DOI: 10.1042/cs20190666.
Li GM, Wang YG, Pan Q, et al., 2014, RNAi Screening with shRNAs against Histone Methylation-related Genes Reveals Determinants of Sorafenib Sensitivity in Hepatocellular Carcinoma Cells. Int J Clin Exp Pathol, 7:1085–92.
Chen Y, Yang S, Hu J, et al., 2016, Increased Expression of SETD7 Promotes Cell Proliferation by Regulating Cell Cycle and Indicates Poor Prognosis in Hepatocellular Carcinoma. PLoS One, 11:e0154939. DOI: 10.1371/journal.pone.0154939.
Gu Y, Wang X, Liu H, et al., 2018, SET7/9 Promotes Hepatocellular Carcinoma Progression through Regulation of E2F1. Oncol Rep, 40:1863–74. DOI: 10.3892/or.2018.6621.
Wei L, Chiu DK, Tsang FH, et al., 2017, Histone Methyltransferase G9a Promotes Liver Cancer Development by Epigenetic Silencing of Tumor Suppressor Gene RARRES3. J Hepatol, 67:758–69. DOI: 10.1016/j.jhep.2017.05.015.
Zhang J, Jing L, Li M, et al., 2019, Regulation of Histone Arginine Methylation/Demethylation by Methylase and Demethylase (Review). Mol Med Rep, 19:3963–71. DOI: 10.3892/mmr.2019.10111.
Webby CJ, Wolf A, Gromak N, et al., 2009, Jmjd6 Catalyses Lysyl-Hydroxylation of U2AF65, a Protein Associated with RNA Splicing. Science (New York, NY), 325:90–3. DOI: 10.1126/science.1175865.
Yang J, Chen S, Yang Y, et al., 2020, Jumonji Domain-containing Protein 6 Protein and its Role in Cancer. Cell Prolif, 53:e12747. DOI: 10.1111/cpr.12747.
Di Lorenzo A, Bedford MT, 2011, Histone Arginine Methylation. FEBS Lett, 585:2024–31. DOI: 10.1016/j.febslet.2010.11.010.
Huang Y, Vasilatos SN, Boric L, et al., 2012, Inhibitors of Histone Demethylation and Histone Deacetylation Cooperate in Regulating Gene Expression and Inhibiting Growth in Human Breast Cancer Cells. Breast Cancer Res Treat, 131:777–89. DOI: 10.1007/s10549-011-1480-8.
Klose RJ, Kallin EM, Zhang Y, 2006, JmjC-domain-containing Proteins and Histone Demethylation. Nat Rev Genet, 7:715–27. DOI: 10.1038/nrg1945.
Martin C, Zhang Y, 2005, The Diverse Functions of Histone Lysine Methylation. Nat Rev Mol Cell Biol, 6:838–49. DOI: 10.1038/nrm1761.
Black JC, Van Rechem C, Whetstine JR, 2012, Histone Lysine Methylation Dynamics: Establishment, Regulation, and Biological Impact. Mol Cell, 48:491–507. DOI: 10.1016/j.molcel.2012.11.006.
Wan J, Liu H, Yang L, et al., 2019, JMJD6 Promotes Hepatocellular Carcinoma Carcinogenesis by Targeting CDK4. Int J Cancer, 144:2489–500. DOI: 10.1002/ijc.31816.
Chang X, Han J, Pang L, et al., 2009, Increased PADI4 Expression in Blood and Tissues of Patients with Malignant Tumors. BMC Cancer, 9:40. DOI: 10.1186/1471-2407-9-40.
van der Windt DJ, Sud V, Zhang H, et al., 2018, Neutrophil Extracellular Traps Promote Inflammation and Development of Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis. Hepatology (Baltimore, Md), 68:1347–60. DOI: 10.1002/hep.29914.
Lei ZJ, Wang J, Xiao HL, et al., 2015, Lysine-specific Demethylase 1 Promotes the Stemness and Chemoresistance of Lgr5(+) Liver Cancer Initiating Cells by Suppressing Negative Regulators of b-catenin Signaling. Oncogene, 34:3188–98. DOI: 10.1038/onc.2015.129.
Huang M, Chen C, Geng J, et al., 2017, Targeting KDM1A Attenuates Wnt/b-Catenin Signaling Pathway to Eliminate Sorafenib-resistant Stem-like Cells in Hepatocellular Carcinoma. Cancer Lett, 398:12–21. DOI: 10.1016/j.canlet.2017.03.038.
Kim S, Bolatkan A, Kaneko S, et al., 2019, Deregulation of the Histone Lysine-Specific Demethylase 1 is Involved in Human Hepatocellular Carcinoma. Biomolecules, 9:810. DOI: 10.3390/biom9120810.
Wu LW, Zhou DM, Zhang ZY, et al., 2019, Suppression of LSD1 Enhances the Cytotoxic and Apoptotic Effects of Regorafenib in Hepatocellular Carcinoma Cells. Biochem Biophys Res Commun, 512:852–8. DOI: 10.1016/j.bbrc.2019.03.154.
Dong F, Jiang S, Li J, et al., 2019, The Histone Demethylase KDM4D Promotes Hepatic Fibrogenesis by Modulating Toll-like receptor 4 Signaling Pathway. EBioMedicine, 39:472–83. DOI: 10.1016/j.ebiom.2018.11.055.
Deng Y, Li M, Zhuo M, et al., 2020, Histone Demethylase JMJD2D Promotes the Self-renewal of Liver Cancer Stem-like Cells by Enhancing EpCAM and Sox9 Expression. J Biol Chem, 2020:015335. DOI: 10.1074/jbc.ra120.015335.
Xhabija B, Kidder BL, 2019, KDM5B is a Master Regulator of the H3K4-Methylome in Stem Cells, Development and Cancer. Semin Cancer Biol, 57:79–85. DOI: 10.1016/j.semcancer.2018.11.001.
Wang D, Han S, Peng R, et al., 2016, Depletion of Histone Demethylase KDM5B Inhibits Cell Proliferation of Hepatocellular Carcinoma by Regulation of Cell Cycle Checkpoint Proteins p15 and p27. J Exp Clin Cancer Res, 35:37. DOI: 10.1186/s13046-016-0311-5.
Tang B, Qi G, Tang F, et al., 2016, Aberrant JMJD3 Expression Upregulates Slug to Promote Migration, Invasion, and Stem Cell-Like Behaviors in Hepatocellular Carcinoma. Cancer Res, 76:6520–32. DOI: 10.1158/0008-5472.can-15-3029.
Pediconi N, Salerno D, Lupacchini L, et al., 2019, EZH2, JMJD3, and UTX Epigenetically Regulate Hepatic Plasticity Inducing Retro-Differentiation And Proliferation Of Liver Cells. Cell Death Dis, 10:518. DOI: 10.1038/s41419-019-1755-2.
Mann SA, DeMart MK, May B, et al., 2020, Histone H4-based Peptoids are Inhibitors of Protein Arginine Methyltransferase 1 (PRMT1). Biochem J, 477:2971–80. DOI: 10.1042/bcj20200534.
Vedadi M, Barsyte-Lovejoy D, Liu F, et al., 2011, A Chemical Probe Selectively Inhibits G9a and GLP Methyltransferase Activity in Cells. Nat Chem Biol, 7:566–74.
Chang Y, Zhang X, Horton JR, et al., 2009, Structural Basis for G9a-like Protein Lysine Methyltransferase Inhibition by BIX-01294. Nat Struct Mol Biol, 16:312–7. DOI: 10.2210/pdb3fpd/pdb.
Namgung Y, Kim SY, Kim I, 2019, Down-regulation of Survivin by BIX-01294 Pretreatment Overcomes Resistance of Hepatocellular Carcinoma Cells to TRAIL. Anticancer Res, 39:3571–8. DOI: 10.21873/anticanres.13503.
Hwang S, Kim S, Kim K, et al., 2020, Euchromatin Histone Methyltransferase II (EHMT2) Regulates the Expression of Ras-related GTP Binding C (RRAGC) Protein. BMB Rep, 53:576–81. DOI: 10.5483/bmbrep.2020.53.11.055.
Liu F, Barsyte-Lovejoy D, Allali-Hassani A, et al., 2011, Optimization of Cellular Activity of G9a Inhibitors 7-aminoalkoxy-quinazolines. J Med Chem, 54:6139–50. DOI: 10.1021/jm200903z.
Gu M, Toh TB, Hooi L, et al., 2019, Nanodiamond-Mediated Delivery of a G9a Inhibitor for Hepatocellular Carcinoma Therapy. ACS Appl Mater Interf, 11:45427–41. DOI: 10.1021/acsami.9b16323.
Xu G, Xu WY, Xiao Y, et al., 2020, The Emerging Roles of Non-coding Competing Endogenous RNA in Hepatocellular Carcinoma. Cancer Cell Int, 20:496. DOI: 10.1002/pro.3535. DOI: 10.1186/s12935-020-01581-5.